Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alteon (ALT) -- Ignore unavailable to you. Want to Upgrade?

To: Lucky who wrote (192)	12/10/1997 8:26:00 AM
From: Jonathan Rothschild	Read Replies (2) \| Respond to of 318

These diabetes trials take alot longer than other trials. Amylin's extension was no exception. Alteon's drug, aminoguanidine, while protected by a broad patent portfolio, is available real cheap from chemical supply houses. Counterfeiters will jump on it, if and when it's approved. Also look at Monday's press release from Sparta Pharmaceuticals (SPTA), they announced acquisition of a compound which is structurally similar to aminoguanidine and will initiate clinical trials soon with this agent in diabetes patients.